AU2014218569B2 - Nanoparticles for controlled release of anti-biofilm agents - Google Patents

Nanoparticles for controlled release of anti-biofilm agents Download PDF

Info

Publication number
AU2014218569B2
AU2014218569B2 AU2014218569A AU2014218569A AU2014218569B2 AU 2014218569 B2 AU2014218569 B2 AU 2014218569B2 AU 2014218569 A AU2014218569 A AU 2014218569A AU 2014218569 A AU2014218569 A AU 2014218569A AU 2014218569 B2 AU2014218569 B2 AU 2014218569B2
Authority
AU
Australia
Prior art keywords
npc
pct
therapeutic agent
dmaema
biofilm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014218569A
Other languages
English (en)
Other versions
AU2014218569A1 (en
Inventor
Danielle Benoit
Megan L. Falsetta Wood
Marlise I. Klein
Hyun Koo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of AU2014218569A1 publication Critical patent/AU2014218569A1/en
Application granted granted Critical
Publication of AU2014218569B2 publication Critical patent/AU2014218569B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014218569A 2013-02-25 2014-02-25 Nanoparticles for controlled release of anti-biofilm agents Ceased AU2014218569B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361768929P 2013-02-25 2013-02-25
US61/768,929 2013-02-25
PCT/US2014/018211 WO2014130994A1 (en) 2013-02-25 2014-02-25 Nanoparticles for controlled release of anti-biofilm agents

Publications (2)

Publication Number Publication Date
AU2014218569A1 AU2014218569A1 (en) 2015-10-15
AU2014218569B2 true AU2014218569B2 (en) 2018-10-04

Family

ID=51391907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014218569A Ceased AU2014218569B2 (en) 2013-02-25 2014-02-25 Nanoparticles for controlled release of anti-biofilm agents

Country Status (7)

Country Link
US (1) US9566247B2 (https=)
EP (1) EP2958557B1 (https=)
JP (1) JP6309980B2 (https=)
CN (1) CN105142620B (https=)
AU (1) AU2014218569B2 (https=)
CA (1) CA2902157A1 (https=)
WO (1) WO2014130994A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
CN107406556B (zh) * 2015-03-04 2020-07-17 陶氏环球技术有限责任公司 作为用于不良水溶性物质从固体混合物有效增溶的赋形剂的共聚物
WO2017070578A1 (en) 2015-10-21 2017-04-27 The Regents Of The University Of Michigan Detection and treatment of caries and microcavities with nanoparticles
WO2017176796A1 (en) 2016-04-04 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for preventing and treating disease
US20210330599A1 (en) * 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
CN106370636B (zh) * 2016-08-31 2019-02-26 中国科学院新疆生态与地理研究所 一种检测生物膜表面吸附纳米颗粒的方法
EP3585351A4 (en) * 2017-02-23 2020-12-30 Alira Health Boston LLC ECOPHILIC ANTIMICROBIAL FORMULATIONS DISRUPTING BIOFILMS, THEIR DEVELOPMENT AND THEIR USES
BR112019018084A2 (pt) * 2017-03-03 2020-03-24 The Procter & Gamble Company Métodos para quantificar íons em um biofilme dental
EP3612570A4 (en) * 2017-04-17 2021-01-13 The University of Chicago POLYMERIC MATERIALS FOR THE ADMINISTRATION OF SHORT-CHAIN FATTY ACIDS TO THE INTESTINE FOR HUMAN HEALTH AND DISEASE TREATMENT APPLICATIONS
US11291613B2 (en) 2017-05-16 2022-04-05 Johnson & Johnson Consumer Inc. Coated particles and their uses
DE102017130893A1 (de) * 2017-12-21 2019-06-27 Paul Hartmann Ag pH regulierende Wundauflage
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3847442A4 (en) 2018-09-06 2022-10-12 GreenMark Biomedical Inc. SYSTEM FOR TOOTH IMAGING AND/OR HARDENING
CN109091453A (zh) * 2018-09-18 2018-12-28 成都爱睿康美医疗科技有限责任公司 葡萄糖响应性的可注射纳米凝胶及其制备方法和应用
CN113226379A (zh) * 2018-10-22 2021-08-06 武田药品工业株式会社 靶向内体中g蛋白偶联受体的纳米颗粒封装
CN109827814A (zh) * 2019-03-11 2019-05-31 南京大学 一种新型大气颗粒物琼脂采样膜制备及免溶剂提取细胞暴露方法
WO2020198468A1 (en) * 2019-03-26 2020-10-01 Temple University-Of The Commonwealth System Of Higher Education Smart composite with antibiofilm, mineralizing, and antiinfection therapeutic effects
US12195755B2 (en) 2019-05-20 2025-01-14 Brown University Placental lipid bilayer for cell-free molecular interaction studies
DE102019122569A1 (de) 2019-08-22 2021-02-25 Mühlbauer Technology Gmbh Flavonoidderivat
US12509559B2 (en) 2019-10-28 2025-12-30 Brown University Bacterial beta-lactamase responsive hydrogels
US20210179884A1 (en) 2019-12-17 2021-06-17 Columbia Insurance Company Redox chased suspension bead additives for paints and stains
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2023091676A1 (en) * 2021-11-19 2023-05-25 The Regents Of The University Of Michigan Biofilm-targeting nanoparticles to increase the anticaries effect of fluoride
EP4543993A1 (en) 2022-07-11 2025-04-30 Benjamin Moore & Co. Nonionic resins, and mixtures of nonionic resins with cationic additives for stain blocking architectural compositions
CN115671264B (zh) * 2023-01-04 2023-03-07 云南伦扬科技有限公司 一种用于靶向光催化变形链球菌生物膜的级联纳米酶
WO2024226999A1 (en) * 2023-04-28 2024-10-31 Brown University Methods of making and using nanoparticles for treatment of microbial biofilms
CN116570734B (zh) * 2023-07-13 2023-10-13 四川大学华西医院 一种具有靶向功能的核壳壳结构药物胶束及其制备方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
CN118955827B (zh) * 2024-07-31 2025-09-12 安徽农业大学 一种纳米载体及其制备方法和应用
CN120324589B (zh) * 2025-04-17 2026-03-27 陕西佰济生物研发有限公司 一种响应式释放微胶囊及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092575A1 (en) * 2005-05-10 2007-04-26 Naomi Balaban Compositions for administering RNAIII-inhibiting peptides
US20100021391A1 (en) * 2006-07-14 2010-01-28 Montana State University Novel nanoparticles for biofilm targeting

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116602A (en) * 1989-09-27 1992-05-26 Colgate-Palmolive Company Antiplaque oral compositions
BRPI0314042B8 (pt) * 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
WO2005030174A1 (en) 2003-09-23 2005-04-07 Massachusetts Institute Of Technology Ph-triggered microparticles
US8119162B2 (en) * 2005-11-10 2012-02-21 Colgate-Palmolive Company Particles that disrupt or impede bacterial adhesion, related compositions and methods
NZ569756A (en) 2005-12-12 2011-07-29 Allaccem Inc Methods and systems for preparing antimicrobial films and coatings utilising polycyclic bridged ammonium salts
US8188068B2 (en) 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
KR101764427B1 (ko) 2008-05-13 2017-08-02 유니버시티 오브 워싱톤 미셀성 어셈블리
EP2313101A4 (en) * 2008-07-09 2014-05-21 Univ Nebraska FUNCTIONAL MICELLES FOR HARD FIBER-RELATED CHEMICAL RELEASE RELEASE
EP2335073A4 (en) * 2008-09-02 2012-09-26 Univ Maryland DIAGNOSIS OF BIOFILM IN VIVO INFECTION AND TREATMENT
US9089677B2 (en) 2011-01-25 2015-07-28 The Regents Of The University Of California Transcutaneous multimodal delivery system (TMDS)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092575A1 (en) * 2005-05-10 2007-04-26 Naomi Balaban Compositions for administering RNAIII-inhibiting peptides
US20100021391A1 (en) * 2006-07-14 2010-01-28 Montana State University Novel nanoparticles for biofilm targeting

Also Published As

Publication number Publication date
CN105142620B (zh) 2018-09-28
JP6309980B2 (ja) 2018-04-11
CN105142620A (zh) 2015-12-09
WO2014130994A1 (en) 2014-08-28
JP2016509067A (ja) 2016-03-24
EP2958557B1 (en) 2019-11-27
EP2958557A4 (en) 2016-11-30
EP2958557A1 (en) 2015-12-30
CA2902157A1 (en) 2014-08-28
US20150374634A1 (en) 2015-12-31
AU2014218569A1 (en) 2015-10-15
US9566247B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
AU2014218569B2 (en) Nanoparticles for controlled release of anti-biofilm agents
US20210330599A1 (en) Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
Horev et al. pH-activated nanoparticles for controlled topical delivery of farnesol to disrupt oral biofilm virulence
Sims et al. Enhanced design and formulation of nanoparticles for anti-biofilm drug delivery
Xi et al. Dual corona vesicles with intrinsic antibacterial and enhanced antibiotic delivery capabilities for effective treatment of biofilm-induced periodontitis
Baier et al. Enzyme responsive hyaluronic acid nanocapsules containing polyhexanide and their exposure to bacteria to prevent infection
EP2872120B1 (en) Therapeutic nanoparticles with a polymyxin b as targeting agent
Yang et al. Antibacterial activity of nitric oxide-releasing hyperbranched polyamidoamines
Liu et al. Enzymatically biodegradable polyrotaxane–deferoxamine conjugates for iron chelation
Chifiriuc et al. Antibiotic drug delivery systems for the intracellular targeting of bacterial pathogens
Engin et al. Nanoantibiotics: A novel rational approach to antibiotic resistant infections
US20190125896A1 (en) Anti-infective compositions comprising phytoglycogen nanoparticles
US9694085B2 (en) Targeted therapeutic nanoparticles
Phan et al. Self-assembled amphiphilic starch based drug delivery platform: Synthesis, preparation, and interactions with biological barriers
Ramamurthy et al. Structurally nanoengineered antimicrobial peptide polymers: design, synthesis and biomedical applications
Silva-Carvalho et al. Covalent conjugation of amphotericin B to hyaluronic acid: an injectable water-soluble conjugate with reduced toxicity and anti-leishmanial potential
He et al. Development of “Intelligent particles” for the treatment of dental caries
Kumawat et al. pH-responsive, reactive oxygen species scavenging and highly swellable nanogel for colon-targeted oral drug delivery
Dai et al. Protonation–activity relationship of bioinspired ionizable glycomimetics for the growth Inhibition of bacteria
Zhang et al. Simple and cost-effective polycondensation routes to antimicrobial consumer products
US12599673B2 (en) Techniques for enhancing the selectivity and efficacy of antimicrobial and anticancer polymer agents
Soliman et al. Minocycline block copolymer micelles and their anti‐inflammatory effects on microglia
CN104204082B (zh) 高分子化氮氧化合物与无机颗粒的有机-无机杂合复合物
Romanovska Synthesis of amphiphilic antimicrobial polymer-antibiotic conjugates and particle networks
Savin Biomaterials based on modified polysaccharides, micro/nanoparticles and film, for the controlled release of active principles

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired